With files from Island Morning
Khan et al., 2024) if nutritional and behavioural supports are not intensified (Sievenpiper 2026)
Jennifer Hardy May 21, 2025 4 min read If you're thinking about starting a GLP-1 medication for obesity, like Wegovy or Zepbound, youve probably started researching what has to change, especially when it comes to food and drinks
Recently, an oral GLP-1 receptor agonist has demonstrated promising results in phase 3 clinical trials
The key is deciding which product to purchase
Conversely, DKD in type 2 diabetes mellitus shows greater pathological heterogeneity, with some people developing classical glomerular lesions, while others present with atypical features such as prominent tubulointerstitial damage, vascular abnormalities, or coexisting non-DKD pathology [21,22]